

AACR Meeting II 2020 Participation

Presentations

Circulating Tumor DNA for Patient Stratification

[*A multi-gene prostate cancer liquid biopsy with > 92% accuracy in diagnosis and assessment of disease status*](#)

Authors: Kambiz Rahbar, Mark Kidd, Ignat Drozdov, Alexandra Kitz, Anna Malczewska, Pawel Rajwa, Christof Bernemann, Lisa Bodei, **Irvin Modlin**

Session: June 23; 10:05 AM

The Evolving Role of the Pathologist in Cancer Research

[*High-dimensional imaging technologies in pathology diagnosis and cancer research*](#)

Author: David L. Rimm

Abstract: 3

Session: June 23; 12:45 PM

Clinical Trial Design: Part 2: Clinical Trials Issues with Molecularly Targeted Agents

[*Incorporating translational research into clinical trials of targeted agents*](#)

Author: Katerina A. Politi

Session: June 23; 1:15 PM

Cancer Increases in Younger Populations: Where Are They Coming from?

[*Early-onset colorectal cancer*](#)

Author: Xavier Llor

Session: June 23; 1:45 PM

Dharma Master Jiantai Symposium in Biomarkers: High-Dimensional Imaging of Immune and Tumor Cells in Human FFPE Tissue

[*Understanding the immune composition of human lung cancer using multiparametric and spatially resolved tissue analysis*](#)

Author: Kurt Alex Schalper

Session: June 23; 4:00 PM

Cancer Immunity

[*3424 - IL-18 immunotherapy is efficacious against checkpoint-immunotherapy refractory tumors by promoting the maturation of highly proliferative, polyfunctional NK cells*](#)

Authors: Orr-El Weizman, Ting Zhou, William Damsky, Meaghan McGeary, Marcus W. Bosenberg, Aaron M. Ring

Abstract: 3424

Session: June 24; 9:50 AM

Clinical Trial Design: Part 3: Clinical Development of IO Agents
[*Combination strategies with IO agents*](#)

Author: Roy S. Herbst

Session: June 24; 2:15 PM

Posters

Mechanisms of Sensitivity and Resistance to Targeted Therapy 3

[*Genomic, transcriptomic, and epigenetic profiling of triple-negative breast cancer cells after Navitoclax treatment*](#)

Authors: **Michal Marczyk**, Vignesh Gunasekharan, Jun Zhao, Rihao Qu, Xiaotong Li, Gauri A. Patwardhan, Vikram B. Wali, Abhishek K. Gupta, Manoj M. Pillai, Yuval Kluger, Christos Hatzis, B

Abstract: 6333

Poster: 16

Session: June 22; 9:00 AM

Immune Response to Therapies 1

[*VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer*](#)

Authors: **Alicia Ding**, Franz Villarroel-Espindola, Adam Ducler, Brian S. Henick, Shruti Desai, Nicole Gianino, Jon Zugazagoitia, David L. Rimm, Alain Robert, Francisco Cruzalegui, Pierre Ferré, Roy Herbst, Miguel Sanmamed, Lieping Chen, **Kurt A. Schalper**

Abstract: 5525

Poster: 15

Session: June 22; 9:00 AM

Novel Antitumor Agents 2

[*Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma*](#)

Authors: **Elena Bonazzoli**, Stefania Bellone, Luca Zammataro, Barbara Gnutti, Adele Guglielmi, Silvia Pelligra, Paola Manara, Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, **Alessandro D. Santin**

Abstract: 5341

Poster: 30

Session: June 22; 9:00 AM

Immune Cells in the Tumor Microenvironment 4

[*Comparison of tumor immune microenvironment in triple negative breast cancer \(TNBC\) of African American versus that of white patients*](#)

Authors: **Vesal Yaghoobi**, Vasiliki Pelekanou, Tess O'Meara, Andrea Silber, Lajos Pusztai, David Rimm, **Kim Blenman**

Abstract: 4973

Poster: 8

Session: June 22; 9:00 AM

Mechanisms of Drug Action 1

[*Combination of the Aurora A inhibitor TAS-119 and adavosertib results in synergistic c-Jun-mediated cell death in head and neck and lung cancers*](#)

Authors: **Jong Woo Lee**, Cindy Yang, **Barbara Burtness**

Abstract: 604

Poster: 1

Session: June 22; 9:00 AM

Predictive Biomarkers for Treatment Efficacy 1

[*Diagnostic utility of the NETest in neuroendocrine transformed prostate cancer*](#)

Authors: Kambiz Rahbar, Mark Kidd, Ignat Drozdov, Alexandra Kitz, Anna Malczewska, Lisa Bodei, Pawel Rajwa, Christof Bernemann, **Irvin Modlin**

Abstract: 1999

Poster: 7

Session: June 22; 9:00 AM

Predictive Biomarkers for Treatment Efficacy 1

[*Biomarker discovery in immunotherapy-treated melanoma patients with imaging mass cytometry*](#)

Authors: **Sandra Martinez-Morilla**, Franz Villarroel-Espindola, Pok Fai Wong, Harriet Kluger, Maria Toki, Thazin New Aung, Vasiliki Pelekanou, Brian Bourke-Martin, **David L. Rimm**

Abstract: 2001

Poster: 9

Session: June 22; 9:00 AM

Predictive Biomarkers for Treatment Efficacy 1

[*Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC*](#)

Authors: **Yuting Liu**, Jon Zugazagoitia, Kurt A. Schalper, Roy S. Herbst, **David L. Rimm**

Abstract: 2002

Poster: 10

Session: June 22; 9:00 AM

Adaptive Immunity to Tumors

[*IL-18 pathway agonism expands intratumoral PD1+ Tcf1+ stem-like CD8+ cells and their polyfunctional effector progeny to promote anti-tumor immunity*](#)

Authors: **Ting Zhou**, Orr-El Weizman, William Damsky, Meaghan McGeary, Marcus W. Bosenberg, **Aaron M. Ring**

Abstract: 2156

Poster: 17

Session: June 22; 9:00 AM

Mechanisms of DNA Damaging Therapeutics

[*Exploiting inherent DNA damage repair defects in IDH1/2 mutated gliomas with the CNS penetrant PARP inhibitor, pamiparib*](#)

Authors: **Christopher Hong**, Amrita Sule, Jason Beckta, Ranjini Sundaram, **Ranjit Bindra**

Abstract: 1389

Poster: 25

Session: June 22; 9:00 AM

Circulating Markers 3

[*Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signatures*](#)

Authors: **Ioannis A. Vathiotis**, Jason Reeves, Maria Toki, Pok Fai Wong, Harriet Kluger, Thazin Nwe Aung, Konstantinos N. Syrigos, Sarah Warren, **David L. Rimm**

Abstract: 3095

Poster: 5

Session: June 22; 9:00 AM

Immune Checkpoints 1

[*Quantitative assessment of CD200 and CD200R expression in lung cancer*](#)

Authors: **Ioannis A. Vathiotis**, Tyler MacNeil, Jon Zugazagoitia, Sandra Martinez-Morilla, Fahad Ahmed, Konstantinos N. Syrigos, Aaron M. Gruver, Kyla Driscoll, **David L. Rimm**

Abstract: 937

Poster: 20

Session: June 22; 9:00 AM

Mechanisms of Resistance and Sensitivity to EGFR Targeting

[*Hypoxia induces EGFR inhibitor resistance in lung cancer cells by upregulation of fibroblast growth factor receptor 1 \(FGFR1\) via MAPK pathway*](#)

Authors: **Yuhong Lu**, Yanfeng Liu, Sebastian Oeck, Gary J. Zhang, **Peter M. Glazer**

Abstract: 1877

Poster: 21

Session: June 22; 9:00 AM

Preclinical Advances and Novel Cell Cycle Targets

[*Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer models*](#)

Authors: **Zhigui Li**, Jing Ji, **Gloria S. Huang**

Abstract: 4851

Poster: 13

Session: June 22; 9:00 AM

Innovative Assay Technologies

[*Novel seroprofiling assay reveals previously undescribed autoantibody responses in immunotherapy treated cancer patients*](#)

Authors: Connor E. Rosen, Yile Dai, Miguel F. Sanmamed, **Aaron M. Ring**

Abstract: 6292

Poster: 5

Session: June 22; 9:00 AM

New Imaging-based Approaches to Plan, Monitor, and Augment Cancer Treatment

[*Mapping the extracellular pH gradient of colorectal cancer after immuno-thermal ablation*](#)

Authors: **Daniel Coman**, Johannes M. Ludwig, **Hyun S. Kim**

Abstract: 2778

Poster: 10

Session: June 22; 9:00 AM

Obesity, Physical Activity, and Related Biomarkers

[*Do obese patients present with worse breast cancer?*](#)

Authors: **Julian Huang, Anees Chagpar**

Abstract: 3502

Poster: 21

Session: June 22; 9:00 AM

Signaling through Growth Factor Receptors, Kinases, and Phosphatases in Cancer

[*PPP6C regulation of ERK signaling in melanoma*](#)

Authors: **Eunice Cho, Hua Jane Lou, Benjamin E. Turk**

Abstract: 3754

Poster: 8

Session: June 22; 9:00 AM

Modulation of DNA Repair, New Nonclinical Models for Targets, and Other Targets

[*Characterization of ATRX loss combined with IDH1 R132H mutation in gliomas*](#)

Authors: **Jennifer Garbarino, Ranjit Bindra, Ryan Jensen**

Abstract: 4134

Poster: 11

Session: June 22; 9:00 AM

Model Organisms for Cancer Research

[*Role of aldehyde dehydrogenase 1B1 in colon carcinogenesis in a newly developed mouse model*](#)

Authors: Wan Ying Tan, David J. Orlicky, Ying Chen, Yatrik M. Shah, David C.

Thompson, **Vasilis Vasiliou**

Abstract: 6141

Poster: 25

Session: June 22; 9:00 AM

Phase I Clinical Trials

[*An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer \(NSCLC\) cohort*](#)

Authors: **Patricia LoRusso**, Javier García-Corbacho, Fadi S. Braiteh, Anthony Gonçalves, Francesco Ricci, Hiroji Iwata, Marta Capelán, Marie Paule Sablin, Aleix Prat, Molly Catherine Hardebeck, Marta Puig, Dennis Chin-Lun Huang, Mingchi Hsu, Douglas Yee

Abstract: CT165

Session: June 22; 9:00 AM

Late-Breaking Research: Clinical Research 2

[*Efficacy of first-line \(1L\) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic \(R/M\) head and neck squamous cell carcinoma \(HNSCC\): KEYNOTE-048 subgroup analysis*](#)

Authors: **Barbara Burtness**, Danny Rischin, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto De Castro, Amanda Psyrrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuehrer, Brett G. M. Hughes, Ricard Mesia, Nuttapon Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Joy Ge, Ramona Swaby, Burak Gumuscu, Kevin Harrington

Abstract: LB-258

Poster: 2

Session: June 22; 9:00 AM

Epigenetic Targets

[*Prodigiosin inhibits the proliferation and migration of mcf-7 breast cancer cells through the demethylation of mir-200c gene*](#)

Authors: **Lingeng Lu**, Peng LV, Ya Li, Hou Li, Xinyi Chen, **Yong Zhu**

Abstract: 1755

Poster: 14

Session: June 22; 9:00 AM

Mathematical Modeling

[*A computational model for the PI3K/Akt/mTOR pathway predicts PTEN as a negative feedback loop*](#)

Authors: **Kiran Vanaja Radha** Mukherjee, Neal Rosen, **Andre Levchenko**

Abstract: 5506

Poster: 24

Session: June 22; 9:00 AM

Genomics and Genetic Susceptibility

[*Genome-wide interaction scan identifies gene by smoking interaction at 2q21.3 for pancreatic cancer risk*](#)

Authors: Evelina Mocci, William Wheeler, Laufey T. Amundadottir, Donghui Li, Eric J. Jacobs, Gloria M. Petersen, Brian M. Wolpin, Harvey A. Risch, Peter Kraft, Nilanjan Chatterjee, Alison P. Klein, **Rachael Z. Stolzenberg-Solomon**

Abstract: 1213

Poster: 21

Session: June 22; 9:00 AM

Gene and Vector-Based Therapy

[*Development of MAEGI as a new class of immune gene therapy for cancer treatment*](#)

Author: Sidi Chen

Abstract: 4070

Poster: 19

Session: June 22; 9:00 AM

Phase I Clinical Trials

[*A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy \(iNeST\), in patients with locally advanced or metastatic solid tumors*](#)

Authors: **Patricia LoRusso**, Ani Balmanoukian, Sam Klempner, D R. Camidge, Matthew Hellmann, Michael Gordon, Johanna Bendell, Lars Mueller, Rachel Sabado, Patrick Twomey, Leila Delamarre, Jack Huang, Mahesh Yadav, Jingbin Zhang, Patrick McDonald, Felicitas Müller, Evelyn Derhovanessian, Özlem Türeci, Ugur Sahin, Lillian Siu

Abstract: CT-169

Session: June 22; 9:00 AM

Late-Breaking Research: Clinical Research 2

[*Efficacy and safety of AB928 plus modified FOLFOX-6 \(mFOLFOX-6\) in participants with metastatic colorectal cancer \(mCRC\): Initial results at the recommended dose for expansion \(ARC-3\)*](#)

Authors: **Michael Cecchini**, Manuel Modiano, Fadi Braiteh, Olivia S. Gardner, Houston N. Gilbert, Daniel DiRenzo, Lisa Seitz, Matt J. Walters, Fangfang Yin, Rachel Woloski, Melissa C. Paoloni, Ki Y. Chung

Abstract: LB-387

Poster: 11

Session: June 22; 9:00 AM

